drugset / Trial / NCT00181142

The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation

NCT00181142

Phase 2/3 Completed 60 enrolled Johns Hopkins University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare outcomes in patients undergoing lung transplantation, using 2 different induction therapies. Primary outcome is survival and secondary outcomes include freedom from infection and freedom from rejection.

Timeline

Start
1999-10
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Daclizumab Monoclonal antibody

Indications

No indication recorded.